Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism

We recently showed that prenatal exposure to valproic acid (VPA) in mice causes autism-like behavioral abnormalities, including social interaction deficits, anxiety-like behavior and spatial learning disability, in male offspring. In the present study, we examined the effect of prenatal VPA on cognitive function and whether the effect is improved by chronic treatment with VPA and sodium butyrate, histone deacetylase inhibitors. In addition, we examined whether the cognitive dysfunction is associated with hippocampal dendritic morphological changes. Mice given prenatal exposure to VPA exhibited novel object recognition deficits at 9weeks of age, and that the impairment was blocked by chronic (5-week) treatment with VPA (30mg/kg/d, i.p.) or sodium butyrate (1.2g/kg/d, i.p.) starting at 4weeks of age. In agreement with the behavioral findings, the mice prenatally exposed to VPA showed a decrease in dendritic spine density in the hippocampal CA1 region, and the spine loss was attenuated by chronic treatment with sodium butyrate or VPA. Furthermore, acute treatment with sodium butyrate, but not VPA, significantly increased acetylation of histone H3 in the hippocampus at 30min, suggesting the difference in the mechanism for the effects of chronic VPA and sodium butyrate. These findings suggest that prenatal VPA-induced cognitive dysfunction is associated with changes in hippocampal dendritic spine morphology. •Prenatal valproic acid (VPA) exposure caused cognitive impairment in mice.•Prenatal VPA also decreased dendritic spine density in the hippocampus.•Postnatal chronic VPA or sodium butyrate improved the behavioral changes.•Postnatal treatment with the drugs improved the dendritic spine changes.•The behavioral impairment is associated with the dendritic morphological change.